bernstein karen us customs data english  about products  pricing products pricing free customs data buyer services blog gbi login log in or join free shipments products shipments search reduce risk join now m shipment records competitor shipment tracking  manufacturers company reviews filter suppliers by relationship  million products join free bernstein karen track shipments shipment profile  export shipment  import shipment weitzman tel avivyafo ta israel export history shipment exporter importer description departure arrival bernstein karen bernstein karen k  pieces  packages of household go ods haifa  new yorknewark area newark new jersey view more shipments import history shipments exporter importer description departure arrival bernstein karen bernstein karen k  pieces  packages of household go ods haifa  new yorknewark area newark new jersey view more shipments shipment history get access to  million shipment records shipment profiles  company tracking view now trade partners view this companys top trade partners see the number and percentage of shipments from each view now weights  quantities shipment weight kg min avg max    average quantity  items trade partners  shipping routes origin port shipments destination port haifa  new yorknewark area newark new jersey view more routes location weitzman tel avivyafo ta israel share recently viewed products extrusion machine manufacturers  suppliers   products wicking fabric manufacturers  suppliers   products massager slipper manufacturers  suppliers   products bunting manufacturers  suppliers   products bottle washing machine manufacturers  suppliers   products popular products on tradesparq polycarbonate solid sheet manufacturers  suppliers   products hand gun manufacturers  suppliers   products solar power generator manufacturers  suppliers   products pagoda tent manufacturers  suppliers   products subwoofers manufacturers  suppliers   products × message send this inquiry to similar products recipient invite to connect  all fields required at no time will tradesparq make your email available to other users without your permission see our privacy policy close send message achaogen appoints dr karen bernstein to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 99 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street achaogen appoints dr karen bernstein to its board of directors globenewswire jul    am edt south san francisco calif july   globe newswire  achaogen inc nasdaqakao a latestage biopharmaceutical company developing innovative antibacterials addressing multidrug resistant mdr gramnegative infections today announced the appointment of dr karen bernstein cofounder and chairman of biocentury inc to its board of directors dr bernstein brings to achaogen significant leadership and three decades of experience writing and publishing on biotechnology developments in addition the company announced that effective july   alan colowick md mph will step down as a board member of the company to focus on his new role as a partner at sofinnova ventures karens extensive knowledge of what makes biotech companies great is second to none and i am honored to have her join our board as we pursue regulatory approval of our lead product candidate plazomicin and continue to advance our pipeline including the clinical development of our second product candidate cscape karens insights will prove invaluable to achaogen said kenneth hillan mb chb achaogens chief executive officer in addition alans counsel will be greatly missed and i wish to thank him for his outstanding contributions to our board over the past two years i have followed the mounting issue of multidrug antibiotic resistance and wholeheartedly support achaogens mission to address this public health crisis that over the years has worsened because inadequate therapeutic options contribute to high rates of mortality said dr bernstein i am excited to join the achaogen board and to contribute my insights as the company continues to build on its goal of becoming a leader in the treatment of multidrug resistant gramnegative infections about dr bernstein dr bernstein is currently the chairman of biocentury inc which she cofounded and for which she was chairman and editorinchief from 99 to  dr bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of the worldview  most influential people in biotech today by scientific american  and receiving a special recognition award at the american liver foundations salute to excellence honoring individuals who have made an outstanding contribution to biotechnology and medical innovation  dr bernstein holds a phd in political science from stanford university and a ba in politics and history from brandeis university where she served for many years as a member of the brandeis university science advisory council she is on the board of trustees of the keck graduate institute kgi of the applied life sciences and is a member of the board of advisors of kgis school of pharmacy she is a director at ovid therapeutics inc which is focused on developing drugs for orphan diseases of the brain from september  to october  she also served on the board of directors of vitae pharmaceuticals inc which was acquired by allergan plc if you liked this article you might like  sectors that will profit bigtime from oils crash oil prices are tumbling down bad news for companies and petro states but great news at the pump and for these ten industries eric reed jul    pm edt trading action has improved heres what i am playing market players are sorting out the winners and losers and that produces good opportunities if we keep on digging rev shark jan    am est jump on harley davidson but stay away from costamare mad money lightning round jim cramer likes harley and enterprise products partners but says stay away from costamare and achaogen scott rutt jan 9  9 am est earnings not just the trump rally drive stocks cramers mad money recap wednesday  jim cramer explains how bullish comments from one semiconductor equipment maker lifts shares throughout the sector scott rutt jan   9 pm est trending apples iphone  is coming and it could be in your hands very soon tesla headlines this lineup of  amazing new cars for  heres how you can get a decent job at amazon on august  accepting paypal could make amazon even more of a beast facebook just gave a glimpse into one of its big new business areas advertising partners 99 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers bernstein karens phone number email address  spokeo contact us  close achaogen appoints dr karen bernstein to its board of directors nasdaqakao english français register sign in achaogen appoints dr karen bernstein to its board of directors july    et  source achaogen inc south san francisco calif july   globe newswire  achaogen inc nasdaqakao a latestage biopharmaceutical company developing innovative antibacterials addressing multidrug resistant mdr gramnegative infections today announced the appointment of dr karen bernstein cofounder and chairman of biocentury inc to its board of directors dr bernstein brings to achaogen significant leadership and three decades of experience writing and publishing on biotechnology developments in addition the company announced that effective july   alan colowick md mph will step down as a board member of the company to focus on his new role as a partner at sofinnova ventures “karen’s extensive knowledge of what makes biotech companies great is second to none and i am honored to have her join our board as we pursue regulatory approval of our lead product candidate plazomicin and continue to advance our pipeline including the clinical development of our second product candidate cscape karen’s insights will prove invaluable to achaogen” said kenneth hillan mb chb achaogens chief executive officer “in addition alan’s counsel will be greatly missed and i wish to thank him for his outstanding contributions to our board over the past two years “i have followed the mounting issue of multidrug antibiotic resistance and wholeheartedly support achaogen’s mission to address this public health crisis that over the years has worsened because inadequate therapeutic options contribute to high rates of mortality” said dr bernstein i am excited to join the achaogen board and to contribute my insights as the company continues to build on its goal of becoming a leader in the treatment of multidrug resistant gramnegative infections” about dr bernstein dr bernstein is currently the chairman of biocentury inc which she cofounded and for which she was chairman and editorinchief from 99 to  dr bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of the worldview  most influential people in biotech today by scientific american  and receiving a special recognition award at the american liver foundations salute to excellence honoring individuals who have made an outstanding contribution to biotechnology and medical innovation  dr bernstein holds a phd in political science from stanford university and a ba in politics and history from brandeis university where she served for many years as a member of the brandeis university science advisory council she is on the board of trustees of the keck graduate institute kgi of the applied life sciences and is a member of the board of advisors of kgis school of pharmacy she is a director at ovid therapeutics inc which is focused on developing drugs for orphan diseases of the brain from september  to october  she also served on the board of directors of vitae pharmaceuticals inc which was acquired by allergan plc about achaogenachaogen is a latestage biopharmaceutical company passionately committed to the discovery development and commercialization of innovative antibacterial treatments for mdr gramnegative infections achaogen is developing plazomicin achaogen’s lead product candidate for the treatment of serious bacterial infections due to mdr enterobacteriaceae including carbapenemresistant enterobacteriaceae the food and drug administration has granted plazomicin breakthrough therapy designation for the treatment of bloodstream infections bsi caused by certain enterobacteriaceae in patients who have limited or no alternative treatment options achaogen’s plazomicin program is funded in part with a contract from the biomedical advanced research and development authority plazomicin is the first clinical candidate from achaogen’s gramnegative antibiotic discovery engine and achaogen has other programs in early and late preclinical stages focused on other mdr gramnegative infections all product candidates are investigational only and have not been approved for commercialization for more information please visit wwwachaogencom forwardlooking statementsthis press release contains forwardlooking statements all statements other than statements of historical facts contained herein are forwardlooking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the private securities litigation reform act of 99 including but not limited to achaogen’s expectations regarding potential regulatory approval of plazomicin achaogen’s commercial objectives and achaogen’s pipeline of product candidates such forwardlooking statements involve known and unknown risks uncertainties and other important factors that may cause achaogens actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by the forwardlooking statements such risks and uncertainties include among others the uncertainties inherent in the preclinical and clinical development process the risks and uncertainties of the regulatory approval process the risks and uncertainties of commercialization and gaining market acceptance the risk when bacteria will evolve resistance to plazomicin achaogens reliance on thirdparty contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate achaogens patents or proprietary rights and the risk that achaogens proprietary rights may be insufficient to protect its technologies and product candidates for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to achaogens business in general see achaogens current and future reports filed with the securities and exchange commission including its quarterly report on form q for the fiscal quarter ended march   filed on may   achaogen does not plan to publicly update or revise any forwardlooking statements contained in this press release whether as a result of any new information future events changed circumstances or otherwise contacts matthew duffy investors 9 matthewlifesciadvisorscom denise powell media 99 deniseredhousecommscom related articles other press releases by achaogen inc achaogen wins carbx funding award to advance development of lpxc inhibitor antibiotic to fight drug resistant infections july    achaogen announces new employment inducement grants july    achaogen announces new employment inducement grants june    achaogen highlights data demonstrating potential of plazomicin against mdr gramnegative bacteria at asm microbe  annual meeting june    achaogen initiates cscape clinical development program with phase  study of orallyadministered antibacterial candidate june    profile achaogen inc   subscribe via rss  subscribe via atom  javascript south san francisco california united states contact data contacts matthew duffy investors 9 matthewlifesciadvisorscom denise powell media 99 deniseredhousecommscom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files achaogen inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca 9 phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved sdi learns from  karen erlichman and wendie bernstein lash  spiritual directors international secure store search cart  product products empty no products to be determined shipping  total check out product successfully added to your shopping cart quantity total there are  items in your cart there is  item in your cart total products total shipping  to be determined total continue shopping proceed to checkout menusdiworldhomemembershipeducational eventspresence journalsubscriptionsissueswebinarsguidelines and brochuresvideos and recordingsvideosrecordingsdonatemembershippresence journalsubscriptionsissueseducational eventswebinarsdonate  videossdi learns from  karen erlichman and wendie bernstein lash videos membership educational events presence journal subscriptions issues webinars guidelines and brochures videos and recordings videos recordings donate view larger sdi learns from  karen erlichman and wendie bernstein lash reference condition new productkaren erlichman and wendie bernstein lash talk about the shadow and musar practice in spiritual direction more details warning last items in stock availability date tweet share pinterest send to a friend send to a friend sdi learns from  karen erlichman and wendie bernstein lashkaren erlichman and wendie bernstein lash talk about the shadow and musar practice in spiritual direction recipient  name of your friend   email address of your friend    required fields send   or  cancel print  quantity the minimum purchase order quantity for the product is  member discount  noyes add to cart more infokaren erlichman and wendie bernstein lash talk about the shadow and musar practice in spiritual direction karen erlichman is a licensed clinical social worker in private practice in san francisco california usa where she provides psychotherapy spiritual direction and supervision she trained as a circle of trust facilitator at the center for courage and renewal wendie bernstein lash is a spiritual director supervisor and pilates instructor in redwood city california usa wendie teaches in the morei derekh jewish spiritual direction program and authored two cds  blessings chant and sacred relaxation meditationdvd video achaogen appoints dr karen bernstein to its board of directors  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search see headlines for akao view print version more from globenewswire achaogen wins carbx funding award to advance development of lpxc inhibitor antibiotic to fight drug resistant infections achaogen announces new employment inducement grants achaogen appoints dr karen bernstein to its board of directors referenced stocks akao  rate it achaogen appoints dr karen bernstein to its board of directors by globenewswire  july    am edt vote up a a a south san francisco calif july   globe newswire  achaogen inc nasdaqakao a latestage biopharmaceutical company developing innovative antibacterials addressing multidrug resistant mdr gramnegative infections today announced the appointment of dr karen bernstein cofounder and chairman of biocentury inc to its board of directors dr bernstein brings to achaogen significant leadership and three decades of experience writing and publishing on biotechnology developments in addition the company announced that effective july   alan colowick md mph will step down as a board member of the company to focus on his new role as a partner at sofinnova ventures karens extensive knowledge of what makes biotech companies great is second to none and i am honored to have her join our board as we pursue regulatory approval of our lead product candidate plazomicin and continue to advance our pipeline including the clinical development of our second product candidate cscape karens insights will prove invaluable to achaogen said kenneth hillan mb chb achaogens chief executive officer in addition alans counsel will be greatly missed and i wish to thank him for his outstanding contributions to our board over the past two years i have followed the mounting issue of multidrug antibiotic resistance and wholeheartedly support achaogens mission to address this public health crisis that over the years has worsened because inadequate therapeutic options contribute to high rates of mortality said dr bernstein i am excited to join the achaogen board and to contribute my insights as the company continues to build on its goal of becoming a leader in the treatment of multidrug resistant gramnegative infections about dr bernsteindr bernstein is currently the chairman of biocentury inc which she cofounded and for which she was chairman and editorinchief from 99 to  dr bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of the worldview  most influential people in biotech today by scientific american  and receiving a special recognition award at the american liver foundations salute to excellence honoring individuals who have made an outstanding contribution to biotechnology and medical innovation  dr bernstein holds a phd in political science from stanford university and a ba in politics and history from brandeis university where she served for many years as a member of the brandeis university science advisory council she is on the board of trustees of the keck graduate institute kgi of the applied life sciences and is a member of the board of advisors of kgis school of pharmacy she is a director at ovid therapeutics inc which is focused on developing drugs for orphan diseases of the brain from september  to october  she also served on the board of directors of vitae pharmaceuticals inc which was acquired by allergan plc about achaogenachaogen is a latestage biopharmaceutical company passionately committed to the discovery development and commercialization of innovative antibacterial treatments for mdr gramnegative infections achaogen is developing plazomicin achaogens lead product candidate for the treatment of serious bacterial infections due to mdr enterobacteriaceae including carbapenemresistant enterobacteriaceae the food and drug administration has granted plazomicin breakthrough therapy designation for the treatment of bloodstream infections bsi caused by certain enterobacteriaceae in patients who have limited or no alternative treatment options achaogens plazomicin program is funded in part with a contract from the biomedical advanced research and development authority plazomicin is the first clinical candidate from achaogens gramnegative antibiotic discovery engine and achaogen has other programs in early and late preclinical stages focused on other mdr gramnegative infections all product candidates are investigational only and have not been approved for commercialization for more information please visit wwwachaogencom forwardlooking statementsthis press release contains forwardlooking statements all statements other than statements of historical facts contained herein are forwardlooking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the private securities litigation reform act of 99 including but not limited to achaogens expectations regarding potential regulatory approval of plazomicin achaogens commercial objectives and achaogens pipeline of product candidates such forwardlooking statements involve known and unknown risks uncertainties and other important factors that may cause achaogens actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by the forwardlooking statements such risks and uncertainties include among others the uncertainties inherent in the preclinical and clinical development process the risks and uncertainties of the regulatory approval process the risks and uncertainties of commercialization and gaining market acceptance the risk when bacteria will evolve resistance to plazomicin achaogens reliance on thirdparty contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate achaogens patents or proprietary rights and the risk that achaogens proprietary rights may be insufficient to protect its technologies and product candidates for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to achaogens business in general see achaogens current and future reports filed with the securities and exchange commission including its quarterly report on form q for the fiscal quarter ended march   filed on may   achaogen does not plan to publicly update or revise any forwardlooking statements contained in this press release whether as a result of any new information future events changed circumstances or otherwise contacts matthew duffy investors 9 matthewlifesciadvisorscomdenise powell media 99 deniseredhousecommscom source achaogen inc this article appears in news headlines referenced stocks akao latest news video login please enable javascript to view the comments powered by realtidbits related stocks articles subscribe silicon labs rides internet of things strength to another great quarter   pm ryzen and cryptocurrency drive growth for amd   pm mercadolibre is beating amazon at its own game   pm closex signin existing nasdaqcom member log in here by signing into to the site using any of the thirdparty services above you agree to nasdaqcoms terms of use welcome back log in using your   account switch accounts highest rated articles of last week shareholders approve major structural change to top performing merck and pfizer collaborate with corning to modernize  yatra attains leadership position in corporate travel with the miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated todays market activity nasdaq    ▲   djia  9  ▲   sp     ▲   data as of jul   try for free nasdaq livequotes platform view all upcoming earnings company expected report date aapl jul   odfl jul   fb jul   tsla aug   t jul   amzn jul   vz jul   ge jul   earnings calendar closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex services  bernstein karen s md park ridge il   ypcomstart your search by typing in the business name below what do you want to find wheremy current locationsearchhomephysicians  surgeons near park ridge ilbernstein karen s mdservicesbernstein karen s md dempster st park ridge il  9view business detailsservicesfish and chips found in  dishphysicians general practitionersimmunizationsto take advantage of this special pricing you must pay without using your insurance you cannot bill thirdparty payers for the physical care must be provided at an advocate medical group immediate care or advocate clinic at walgreens location by a nurse practitioner or other advanced practice clinician not by a physician immunizations are excludedosteoporosisarthritisprimary carewith more than  doctors and advanced practice clinicians amg offers expert primary care and a full range of specialty services from chicagoland to central illinois after your first visit youll gain access to myadvocate find a doctorneurologistsneurologycarpal tunnel syndromemultiple sclerosisepilepsyradiologistmammographycomputed tomographyinterventional radiologyradiologyadvocate excels in addressing the top health care concerns of women our systemwide clinical excellence in mammography program is one example we offer the newest technology and highest quality standards our specially trained nurses and radiology technologists provide you with support education and assistance and are there for you every step of the wayinternistscancer careinternal medicinesurgeonsorthopedicsnew or existing patient of lincolnshire  orthopedics click here to view patient resources and education these forms include new patient demographic health history patient financial policy authorization for release of information and hipaa forms these pages also contains pre and post operation informationsciaticaarthroscopyankle surgeryneurosurgerythe new neurosurgery team at amg offers advanced therapies and clinical experience to provide personal and comprehensive neurosurgical carevascular surgeryarthroscopygynecologistsobstetricsour obstetrics program delivers the vast experience of our network of doctors for assurance from preconception through pregnancy delivery and new mom and baby care our commitment to womens unique health needs is also evident in noninvasive painfree techniques such as dexa scanning for osteoporosis—a dangerous thinning of bonespregnancydermatologistscysteczemaphysical therapistssports medicineorthopedics advocate medical group is renowned for its exceptional orthopedic care for adults children and adolescents our orthopedic surgeons provide a wide variety of subspecialties in orthopedics including sports injuries arthritic conditions workers compensation injuries sprains strains shoulder disorders fracture care and complex hand disordersneck painback painpsychiatristsmental healthyour decisions may include health care power of attorney living will donot resuscitate order and mental health treatment preference declarationsend to phonebernstein karen s md dempster st park ridge il  9send this business listing as a text message to a mobile phonei agree to the terms and conditionscancelsendyour text message was sentto opt out at anytime send the word stop to ypto get a help message send the word help to ypthere was an error sending your textplease try againemailbernstein karen s md dempster st park ridge il  9send this business details to yourself or up to  friendsup to  email addresses separate addresses with a commasend yourself a copycancelsend we just redesigned ypcom do you like it× likenot a fan× thank youfeedback bernstein ip menu bernstein ip is a boutique law firm based in manhattan we offer a full range of legal services sometimes at a flat rate related to branding of products and businesses including prosecution and litigation of domestic and international trademarks and service marks as well as advice and counseling on copyright issues the firm also concentrates a large portion of its practice in connection with international internet law issues with a focus on internet registries and new gtlds we strive to give value and attention to our clients in many ways contact us now karen bernstein media  press appearances